Transfuse | Transplant | Transform a life
What We Do
Immucor is a leading provider of transfusion and transplantation diagnostic products worldwide. We strive to create a world where anyone, anywhere in need of blood or transplantation gets the right blood or transplant that is safe, accessible and affordable.
- Each year, more than 4.5 million people in the U.S. alone need a blood transfusion and approximately 118 million units of blood are collected globally per the World Health Organisation.
- According to the Global Observatory on Donation and Transplantation, there were about 136,976 solid organ transplants in 2020 worldwide.
With today’s dual focus on improving health outcomes and lowering healthcare costs, preventing negative reactions through better-matched donations is the ultimate goal in transfusion and transplantation medicine.
With the right match, we can transform a life together.
Labs We Serve
President and Chief Executive Officer
Avi Pelossof was named President and CEO for Immucor in January 2018.
With more than two decades of experience in diagnostics, Pelossof joined Immucor from Alere, a global leader in point-of-care diagnostics. Most recently, he served as global president of Alere’s $750 million infectious disease business unit. Pelossof has held a variety of senior positions with Alere since January 2007.
Prior to Alere, Pelossof held leadership positions for Chembio Diagnostics Systems, Inc., a developer, manufacturer and distributor of point-of-care diagnostic tests. He also held various positions focused on Latin America at Citibank, N.A./Citigroup and founded the consulting firm The IMS Group, Inc., which provided strategic market development for companies seeking to expand into Latin America. Pelossof has a BA in Economics from the University of Michigan and an MBA in Finance and International Business from New York University.
Chief Operating Officer and Chief Financial Officer
Dominique Petitgenet was named vice president and chief financial officer for Immucor in March 2012 and named chief operating officer in June 2017. Previously, Petitgenet served as chief financial officer and vice president, international transfusion diagnostics from May 2014 to December 2015 and as chief financial officer and vice president, worldwide operations from December 2015 to June 2017.
He joined Immucor from Merial, a division of Sanofi, where he served as chief financial officer. Merial is a multibillion-dollar worldwide leader in the animal health industry with sales in 150 countries. Petitgenet has held a variety of leadership positions with Merial since 2001. Previously, Petitgenet held positions with Rhodia, Rhone-Poulenc Group and the Montedison Group. He earned his master’s degree in finance from Paris Dauphine University.